All News

21 December 2009

Seattle Genetics Announces Antibody-Drug Conjugate Collaboration with GlaxoSmithKlineAntibodies

21 December 2009

UCB announces initial clinical trial results involving patients taking certolizumab pegol for moderate to severe Crohn’s diseaseAntibodies

18 December 2009

Herceptin receives positive opinion in record time for the treatment of HER2-positive advanced stomach cancer in EuropeAntibodies

18 December 2009

Thallion Announces Letter of Intent with LFB Biotechnologies to Develop and Commercialize Shigamabs®Antibodies

18 December 2009

Cangene receives a positive opinion from the European Medicines Agency (“EMA”) for Hepatitis B productAntibodies

18 December 2009

Amgen Receives CHMP Positive Opinion for Prolia(TM) (Denosumab) in the European UnionAntibodies

17 December 2009

Adimab Announces New Antibody Discovery Collaborations and Achievement of Milestones in Two Existing PartnershipsAntibodies

16 December 2009

ABLYNX INITIATES PHASE I FOR ALX-0141 (ANTI-RANKL)Antibodies

15 December 2009

Seattle Genetics and Millennium: The Takeda Oncology Company Announce Strategic Collaboration for Novel Late Stage Lymphoma Program Brentuximab Vedotin (SGN-35)Antibodies

15 December 2009

Celldex Therapeutics Presents Positive Results from Phase 2 Study of the Antibody-Drug Conjugate (ADC) Product Candidate CDX-011 in Advanced Breast CancerAntibodies

14 December 2009

New Phase II Study Showed Trastuzumab-DM1 Shrank Tumors in Women With Highly Advanced HER2-positive Breast CancerAntibodies

11 December 2009

Avastin Plus Commonly Used Chemotherapies Improved Progression-Free Survival in Woman Previously Treated with Chemotherapy for Advanced Breast CancerAntibodies

11 December 2009

Data Presented at San Antonio Breast Cancer Symposium Demonstrate Treatment with Denosumab is Superior to the Standard of CareAntibodies

11 December 2009

Genentech and Biogen Idec Announce Positive Results From First Phase III Trial of Ocrelizumab in Rheumatoid ArthritisAntibodies

11 December 2009

Seattle Genetics Announces Termination of Collaboration Agreement with Genentech for Dacetuzumab (SGN-40)Antibodies

10 December 2009

Sanofi-aventis and U.S Biotechnology company Alopexx enter into a collaboration agreement for a novel human monoclonal antibody targeting infectious diseasesAntibodies

8 December 2009

Facet Biotech Presents Scientific Data Regarding Next-Generation Proprietary Protein Engineering TechnologiesAntibodies

8 December 2009

Immunomedics Reports Updated Results of Subcutaneous Humanized Anti-CD20 Antibody Therapy of Lymphoma With VeltuzumabAntibodies

8 December 2009

Final Data from Phase 2 Study Confirm High Response Rate of Micromet’s Blinatumomab in Patients with Acute Lymphoblastic LeukemiaAntibodies

8 December 2009

Novo Nordisk licenses IL-21 mAb and patent rights to IL-21 antibodies from ZymoGeneticsAntibodies

8 December 2009

Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual MeetingAntibodies

8 December 2009

SAR3419 Phase I Study Results in non-Hodgkin’s Lymphoma at ASHAntibodies

8 December 2009

Phase III Data Showed Rituxan Plus Chemotherapy Improved Survival in Patients With Most Common Form of Adult LeukemiaAntibodies

7 December 2009

Immunomedics Announces Preclinical Results of Milatuzumab in B-Cell MalignanciesAntibodies

7 December 2009

Genzyme Phase 3 Trial of Campath/Fludara Combination Shows Potential Benefit in Second-Line CLLAntibodies

7 December 2009

Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITPAntibodies

7 December 2009

Facet Biotech and Bristol-Myers Squibb Report Promising Phase I/II Interim Data for Elotuzumab in Patients with Relapsed Multiple MyelomaAntibodies

7 December 2009

Biotest AG: Immunoconjugate BT-062 shows first data of clinical efficacyAntibodies

7 December 2009

GENMAB ANNOUNCES RG1507 UPDATEAntibodies

7 December 2009

Soliris® Reduced Hemolysis, Decreased Transfusion Requirements and Improved Fatigue in Patients with PNH and Bone Marrow Insufficiency DisordersAntibodies

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

Mesothelin-Targeted Immunotherapy Pipeline Review

CCR8-Targeted Antibody Immunotherapy Pipeline Review

Nectin-4-Targeted Immunotherapy Pipeline Review

CD40 Agonists & CD40/L Antagonists Pipeline Review

Report Package: TCR-Based Antibody and T-Cell Immunotherapy

Denosumab (Prolia & Xgeva) Biosimilars Pipeline Review

Omalizumab (Xolair) Biosimilars & Biosuperiors Pipeline Review

Fibroblast Activation Protein (FAP) Targeted Therapy & Companion Diagnostic Pipeline Review

CAR-M Industry Landscape Analysis: Chimeric Antigen Receptor-Macrophage (CAR-M) Stakeholders, Technologies, Pipeline, Partnering and Financing

Tocilizumab (Actemra/RoActemra) Biosimilar Antibody Pipeline Review